MedTrace Logo

Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab

NCT02868398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-05-11

No results posted yet for this study

Summary

This study monitors the efficacy and safety of Golimumab in maintaining deep remission and quality of life in Ulcerative Colitis patients in deep prolonged remission with Infliximab. Patients will be followed up for one year and they will be assessed with biochemical tests (C-Reactive Protein , Full Blood Count , Faecal Calprotectin),endoscopic evaluation (MAYO Score) and finally histologically.

Conditions

Sponsors & Collaborators

  • Evangelismos Hospital

    lead OTHER

Principal Investigators

  • Nikos Viazis, Director · Evangelismos Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868398 on ClinicalTrials.gov